THE DRUG TREATMENT OF DUODENAL ULCER: PHYSIOLOGICAL CONSIDERATIONS IN THE CHOICE OF THERAPY
1986; Wiley; Volume: 16; Issue: 2 Linguagem: Inglês
10.1111/j.1445-5994.1986.tb01176.x
ISSN0004-8291
Autores Tópico(s)Gastroesophageal reflux and treatments
ResumoAustralian and New Zealand Journal of MedicineVolume 16, Issue 2 p. 263-267 THE DRUG TREATMENT OF DUODENAL ULCER: PHYSIOLOGICAL CONSIDERATIONS IN THE CHOICE OF THERAPY D. B. JONES, D. B. JONES Senior Fellow in Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, CanadaSearch for more papers by this authorR. H. HUNT, Corresponding Author R. H. HUNT Professor and Head, Division of Gastroenterology, Intestinal Disease Research Unit, McMaster University Medical Centre, Hamilton, Ontario, Canada*Dr Richard H. Hunt, Professor and Head, Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5.Search for more papers by this author D. B. JONES, D. B. JONES Senior Fellow in Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, CanadaSearch for more papers by this authorR. H. HUNT, Corresponding Author R. H. HUNT Professor and Head, Division of Gastroenterology, Intestinal Disease Research Unit, McMaster University Medical Centre, Hamilton, Ontario, Canada*Dr Richard H. Hunt, Professor and Head, Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5.Search for more papers by this author First published: April 1986 https://doi.org/10.1111/j.1445-5994.1986.tb01176.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 de Gara CJ, Jones DB, Hunt RH. Acid pepsin disorders: acid and barriers – The sword or ihe shield – A physiological basis for the rational therapy of peptic ulcer. Rec Adv Gastroenterol (In press). 2 Pounder RE, Williams JG, Hunt RH, Vincent SH, Milton-Thompson GJ, Misiewisz JJ. The effects of oral cimetidine on food stimulated gastric acid secretion and 24 hour intragastric acidity. In: WL Burland, MA Simkins, eds. Cimetidine: Proceedings of the Second International Symposium on Histamine Hi-Receptor Antagonists. Amsterdam : Excerpta Medica, 1977; 189– 205. 3 Gledhill T., Howard OM, Buck M., Paul A., Hunt RH. Single nocturnal dose of an H?-receptor antagonist for the treatment of duodenal ulcer. Gut 1983; 24: 904– 8. 4 dc Gara CJ, Burget D., Silletli C., Hunt RH. Is the daytime control of acid secretion really necessary Scand J Gastroenterol 1984; 19: (Suppl. 98): 7. 5 Ireland A., Colin-Jones DG, Gear P., el al. Ranitidine 150 mg twice daily versus 300 mg nightly in treatment of duodenal ulcers. Lancet 1984; 2: 274– 6. 6 McGuigan JE. Safety of cimetidine: an overview. In: S. Cohen, ed. Update: H.-receptor antagonists. New York , NY : Biomedical Information, 1984; 179– 84. 7 Meyrick-Thomas J., Misiewicz JJ. Histamine H, receptor antagonists in the short and long term treatment of duodenal ulcer. Clin Gastroenterol 1984; 13: 501– 42. 8 Kerr GD. Cimetidine. Twice daily administration in duodenal ulcer. – results of the UK and Ireland multicentre study. In: JH Baron, ed. Cimetidine in the 80's. Edinburgh : Churchill Livingstone, 1981; 9– 13. 9 Ekhardt V. Cimetidine. Twice daily administration in duodenal ulcer results of an European multicentre study. In: JH Baron, ed. Cimetidine in the 80's. Edinburgh : Churchill Livingstone; 1981; 14– 20. 10 Zeiloun P., D'Azemar P. International multicentre trial of ranitidine in duodenal ulcer. Comparison with cimetidine. In: JJ Misiewicz, KG Wormsley, eds. The clinical use of ranitidine. Proceedings of the Second International Symposium on Ranitidine. Oxford Medical Publishing Foundation, 1982; 143– 7. 11 Peterson WL, Elashoff J. Placebo in clinical trials of duodenal ulcer: the end of an era Gastroenterology 1980; 79: 585– 8. 12 Howden CW, Jones DB, Hunt RH. Nocturnal doses of H?-receptor antagonists for duodenal ulcer. Lancet 1985; 1: 647– 8. 13 Gustavsson S., Adami HO, Loof A., Nyberg A., Nyren O. Rapid healing of duodenal ulcers with omeprazole: double-blind dose – comparative trial. Lancet 1983; 2: 124– 5. 14 Prichard PJ, Rubinstein D., Jones DB, el al. Omeprazole: double-blind comparison of 10 mg and 30 mg daily for healing duodenal ulcers. Br Med J 1985; 290: 601– 3. 15 Lamers CBHW, Lind T., Moberg S., Jansen JBM.I, Olbe L. Omeprazole in Zollinger-EUison syndrome. New Engl J Med 1984; 310: 758– 61. 16 Hollander D., Tarnawski A., Cummings D., Krause WJ, Gergely H., Zipser RD. Cytoprotective action of antacids against alcohol induced gastric mucosal injury. Morphologic, ultrastruclural and functional time sequence analysis. Gastroenterology 1984; 86: 1114. 17 Milton-Thompson GJ, Wright B., Vincent D., Hunt RH. Comparison of 24 hour intragastric acidity in duodenal ulcer patients on high dose antacid or cimetidine. Gastroenterology 1979; 76: 1158. 18 Peterson WL, Sturdevant RAL, Frankl HD, et al. Healing of duodenal ulcer with an antacid regimen. New Engl J Med 1977; 297: 341– 5. 19 Walan A. Antacids and anticholinergics in the treatment of duodenal ulcer. Clin Gastroenterol 1984; 13: 473– 99. 20 Strom M., Gotthard R., Bodemar G., Walan A. Antacid/anticholinergic, cimetidine and placebo in treatment of active peptic ulcers. Scand J Gastroenterol 1981; 16: 593– 602. 21 Tytgat GNJ, Hamceteman W., Van Olffen GH. Sucralfate, bismuth compounds, substituted benzimidazoles, trimipramine and pirenzepine in the short and long term treatment of duodenal ulcer. Clin Gastroenterol 1984; 13: 543– 68. 22 Siurala M. The possible significance of the central action of trimipramine in the treatment of functional “non-ulcer” dyspepsia and peptic ulcer with masked depression. Scand J Gastroenterol 1979; 15 (Suppl. 58): 57– 8. 23 Feldman M., Schiller LR. Medical therapy of peptic ulcer disease. In: JH Baron, FG Moody, eds. Foregut. Butterworth Int. Medical Reviews 1981; 192– 240. 24 Samloff IM. Inhibition of peptic aggression by sucralfate. A view from the ulcer crater. Scand J Gastroenterol 1983; 18 (Suppl. 83): 7– 11. 25 Hollander D., Tarnawski A., Kraure WJ, Gergely H. The protective effect of sucralfate against alcohol induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastruclural and functional time sequence analysis. Gastroenterology 1985; 88: 366– 74. 26 Vantrappen G., Janssens J., Popiela T., el al. Effect of 15(R)-15-methyl prostaglandin E, (Arbaprostil) on the healing of duodenal ulcer: a double-blind multicentre study. Gastroenterology 1982; 83: 357– 63. 27 Martin DF, Hollanders D., May S.I, Ravenscroft MM, Tweedle DE, Miller JP. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dieitratobismuthate. Lancet 1981; 1: 7– 10. 28 Bianchi Porro G., Lazzaroni M., Petrillo M., de Nicola C. Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrale or maintained with cimetidine. Lancet 1984; 2: 698. 29 Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299– 302. 30 Kang JY, Piper DW. Cimetidine and colloidal bismuth in the treatment of chronic duodenal ulcer: comparison of initial healing and recurrence after healing. Digestion 1982; 23: 73– 9. 31 Gough KR, Bardhan KD, Crowe JP, el al. Ranitidine and cimetidine in prevention of duodenal ulcer relapse. Lancet 1984; 2: 659– 62. Citing Literature Volume16, Issue2April 1986Pages 263-267 ReferencesRelatedInformation
Referência(s)